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Purine biosynthesis and metabolism, conserved in
all living organisms, is essential for cellular energy
homeostasis and nucleic acid synthesis. The de
novo synthesis of purine precursors is under tight
negative feedback regulation mediated by adenosine
andguaninenucleotides.Wedescribeadistinct early-
onsetneurodegenerativecondition resulting frommu-
tations in theadenosinemonophosphatedeaminase2
gene (AMPD2). Patients have characteristic brain
imaging features of pontocerebellar hypoplasia
(PCH) due to loss of brainstem and cerebellar paren-
chyma. We found that AMPD2 plays an evolutionary
conserved role in the maintenance of cellular guanine
nucleotide pools by regulating the feedback inhibition
of adenosine derivatives on de novo purine synthesis.
AMPD2 deficiency results in defective GTP-depen-
dent initiation of protein translation, which can be
rescuedbyadministrationofpurineprecursors.These
data suggest AMPD2-related PCH as a potentially
treatable early-onset neurodegenerative disease.INTRODUCTION
Neurodegenerative diseases, including Parkinson’s, Alz-
heimer’s, and Huntington diseases, are defined by their progres-
sive loss of structure or function of anatomically defined groups
of neurons. Neurodegenerative diseases affecting children are at
the most severe end of the spectrum, often affecting key regula-
tory enzymes in neuronal function and energy metabolism.
These diseases include lysosomal, peroxisomal, and mitochon-
drial defects such as Tay-Sachs, Zellweger, and Leigh syn-
dromes, respectively, resulting in a host of specific early-onset
neurodegenerative phenotypes. Although significant progress
has been made in the underlying pathogenesis for both the adult
and pediatric forms of disease, treatment currently remains out
of reach for most patients (Thompson and Levitt, 2010).
Much of cerebellar growth occurs after birth (Rakic and
Sidman, 1970), and therefore, early onset degeneration is impos-
sible to differentiate from hypoplasia. Pontocerebellar hypopla-
sia (PCH) represents a group of rare inherited progressive
neurodegenerative disorders with prenatal onset and up to
seven subtypes with clear evidence for time-dependent loss of
brain parenchyma (Barth, 1993; Maricich et al., 2011; Namavar
et al., 2011). The defect is observed at birth, and thus the condi-
tion was initially considered as a hypoplasia, but degenerativeCell 154, 505–517, August 1, 2013 ª2013 Elsevier Inc. 505
features are fully documented (Namavar et al., 2011). Additional
features of PCH include progressive microcephaly, defects of
the corpus callosum, and clinical features of swallowing and
feeding difficulties along with limb spasticity. Death usually re-
sults from chronic medical complications within the first 10 years
of life, and no treatments exist.
Mutations in the evolutionarily conserved transfer RNA (tRNA)
splicing endonuclease (TSEN) complex, including TSEN54,
TSEN34, and TSEN2, were identified in some PCH patients to
date (Budde et al., 2008), presumably implicating a protein syn-
thetic defect in the disorder. In addition, PCH is associated with
mutations in the CHMP1A gene, a regulator of BMI1-INK4A
(Mochida et al., 2012), and in the RNA exosome component
gene EXOSC3 in a subvariant of PCH involving spinal motor
neuron degeneration (Wan et al., 2012). Thus, a host of pathways
regulating RNA biology, polycomb signaling, and protein synthe-
sis interplay in the etiology of PCH.
Purine nucleotide metabolism is one of the most-studied pro-
cesses in biology, critical for synthesis of ATP and guanosine
triphosphate (GTP) tomeet requirements both for energyproduc-
tion and nucleic acid synthesis (Nyhan, 2005). The de novo purine
synthetic pathway initiates with ribose-5-phosphate conversion
to inosine monophosphate (IMP), which is then converted
to either ATP or GTP, depending upon cellular requirements.
The salvage pathway converts hypoxanthine and guanine to
IMP and GMP, respectively, through the enzyme hypoxanthine-
guanine phosphoribosyltransferase (HGPRT) (see Table S1 for
abbreviations, available online),which ismutated in Lesch-Nyhan
syndrome. Adenine salvage to AMP occurs through adenine
phosphoribosyltransferase, which is mutated in some patients
with renal failure. Although these fundamental steps are under-
stood at the biochemical level, the mechanisms of cellular
vulnerability to purine toxicity are not well understood, and other
than in Lesch-Nyhan syndrome, neurological consequences are
rarely described (Camici et al., 2010).
In this study, we identify AMPD2 as necessary for guanine
nucleotide biosynthesis and protein translation. Our data provide
evidence that AMP deaminase activity is critical during neuro-
genesis. We describe a distinct type of PCH in five families
caused by a defect in this enzymatic step that can be overcome
at the cellular level by administration of a purine nucleotide
precursor.
RESULTS
Identification of AMPD2Mutations in a Distinct
Pontocerebellar Hypoplasia-like Syndrome
In order to identify additional causes of pontocerebellar hypopla-
sia, we recruited a cohort of 30 probands and their families with a
presumptive diagnosis of PCH. We previously excluded cases
with overlapping conditions such as Walker-Warburg syndrome,
cortical pachygyria, or evidence of altered metabolism such as
elevations of serum lactate or abnormal peaks on standard clin-
ical serum tandem mass spectroscopy. From these 30 families,
23 had documented parental consanguinity (first or second
cousin marriages), and 21 displayed more than one affected
member, which is consistent with the recessive mode of inheri-
tance for PCH. Of the 30 probands, most had evidence of mild506 Cell 154, 505–517, August 1, 2013 ª2013 Elsevier Inc.to moderate microcephaly, hypotonia/spasticity of the limbs,
and progressive contractures. All patients had the classical
MRI features of PCH (cerebellum and pontine size reduced at
least by 50%) and were enrolled in this institutional review board
(IRB)-approved genetic study.
Exome sequence was generated in 68 individuals from either
two probands (from multiplex families) or both parents and
affected (from simplex families) and interrogated for homo-
zygous, compound heterozygous, and de novo sequence
changes and compared with our in-house database from 1,500
Middle Eastern exomes. One family each had a demonstrable
mutation in EXOSC3 and TSEN2, and three families had muta-
tions in TSEN54, all of which were predicted to be damaging to
protein function and segregated according to a strictly recessive
mode of inheritance. The results validated our recruitment strat-
egy for PCH and suggested additional causes in the remaining
families. Although several potentially mutated genes emerged
from this screen, one was recurrent—the adenosine monophos-
phate deaminase-2 gene (AMPD2).
AMPD2 encodes one of three known AMP deaminase homo-
logs, which converts AMP to IMP. In total, five unique homozy-
gous mutations in AMPD2 were independently identified in this
cohort (Figures 1A and 1B), including two premature stop
codons: one in family PCH-1022 and the other within the most
significant linkage interval in family PCH-1298 (Figure S1A).
The other three mutations occur in a helixes, alter the charge,
polarity, or helical propensity of highly conserved amino acids
(Figures 1C and S1B) (Pace and Scholtz, 1998), and are pre-
dicted to disrupt key hydrogen bonds involved in protein integrity
(Figure S1B) modeled on the solved structure of Arabidopsis
AMP deaminase (Han et al., 2006). Sanger sequencing
confirmed that all five mutations segregated according to a
strictly recessive model of inheritance with full penetrance (Fig-
ure S1C). These variants were not present in our in-house exome
sequences of an additional 1,500 individuals or in publically
available SNP databases. The results suggest that AMPD2 loss
results in PCH.
Comparing brain MRI features among the five patients, we
retrospectively identified a pathognomonic structural brain
anomaly, which we propose as PCH type 9, that is distinct
from other patients with PCH. In all patients, there was hypopla-
sia/atrophy of the cerebellum, with a fluid-filled posterior fossa
(mega cisterna magna) and flattening of the ventral part of the
pons. The unique finding was present on axial images in which
the brainstem takes on a ‘‘figure 8’’ appearance, with relative
preservation of the cerebellar vermis. Therewas also generalized
atrophy of the cerebral cortex and severe corpus callosum hypo-
plasia (Figures 1A and S1D and Table S2), but other organs were
spared.
AMPD2 Is a Functional Ortholog of Yeast AMD1 Gene
AMPD2 is one of three paralogs in mammals mediating the con-
version of AMP to IMP (Bausch-Jurken et al., 1992), which are all
branched from a single ancestral AMP Deaminase gene com-
mon with AMD1 (Figure 2A), the unique AMP deaminase in
Saccharomyces cerevisiae (Meyer et al., 1989). Human AMPD2
has the most sequence similarity to AMD1 (53% identity and
69% similarity over 623 amino acids), as compared with
Figure 1. Recessive Mutations in AMPD2 Cause Loss of Brainstem and Cerebellar Structures, which Is Typical of PCH
(A) Brain MRI from one of the patients for each PCH family. Control child brain MRIs are from the pediatric brain atlas (http://www.seattlechildrens.org/
healthcare-professionals/education/radiology/pediatricbrainatlas/). The top indicates midline sagittal MRI, and the bottom indicates axial MRI at optic chiasm
level. Images show smaller cerebellum (red arrowhead) and brainstem hypoplasia (red arrow) typical of PCH in all patients compared with the control. All patients
show near-complete absence of the corpus callosum. All patients show typical ‘‘figure 8’’ shape of the brainstem (red circle). Corresponding mutation in cDNA (c)
and protein (p) is below each scan. Fs, frame shift; asterisk, stop codon.
(B) Schematic representation of three AMPD2 isoforms. Mutations are indicated relative to their position in cDNA.
(C) Mutated amino acids in PCH are fully conserved.
See also Figure S1 and Table S2.AMPD1 and 3. Individuals with AMPD1 homozygous mutations
display Myoadenylate deaminase deficiency (MIM+102770),
which is possibly the most prevalent genetic disease in humans.
However, only a small percent of homozygous-deficient individ-
uals show symptoms, including exercise-stress-induced accu-
mulation of AMP with resultant muscle weakness and cramping
(Fishbein et al., 1978). AMPD3 shows homozygous inactivating
mutations in healthy individuals (Ogasawara et al., 1987), with
increased adenosine nucleotide levels in erythrocytes (Mende-
lian Inheritance in Man [MIM]: 612874). RT-PCR analysis of the
gene family in human tissue shows expression of AMPD1 pre-
dominantly restricted to muscle but shows AMPD2 and -3 with
widespread expression (Figure S2A).
To determine whether human AMPD2 is a functional ortholog
of yeast AMD1, we expressed AMPD2 in the yeast amd1mutant
(Jones, 1982). As previously reported (Saint-Marc et al., 2009),
this mutant shows a strong germination and/or growth of spore
phenotype in thepresenceof adenine,which is rescuedby forced
expression of yeast AMD1 under the tetracycline response
element (Figure S2B). Presumably, the presence of exogenous
adenine effectively stresses the cells, resulting in further accumu-lation of adenosine nucleotides. Using the same vector system,
we found that human AMPD2 complementary DNA (cDNA)
showed near-complete rescue of growth (Figure 2B).
AMPD2 Mutations Are Deleterious for Protein Function
We next expressed in the yeast amd1mutant each of the identi-
fied patient mutations introduced in the AMD1 gene in order to
test for altered activity. In the presence of doxycycline, AMD1
rescued the amd1 phenotype, but mutated versions of the yeast
gene failed to complement the growth defect (Figure 2C). We
conclude that the patient mutations represent null alleles.
Some residual activity was, however, observed in conditions
of overexpression for corresponding mutations E778D and
R674H (Figure S2C), suggesting that some patient missense
mutations may maintain minimal residual activity.
In order to determine the effect of mutations on protein func-
tion in mammalian cells at physiological expression levels, we
obtained skin fibroblast cultures from patients and one unaf-
fected parent in three different families. AMPD2 protein was
nearly completely absent in patient cells (Figure 2D). By the
assessment of AMP deaminase activity from lysed patient cellsCell 154, 505–517, August 1, 2013 ª2013 Elsevier Inc. 507
Figure 2. Mutations in AMPD2 Cause Protein Instability and Loss of Protein Function
(A) Phylogenic tree representing yeast, mouse, and human AMP deaminase proteins. Scale bar, number of substitutions per site.
(B) 10-fold serial dilutions (left to right) of WT or amd1 yeast strains transformedwith yeast AMD1 or human AMPD2 gene on adenine-supplementedmedia. Yeast
amd1 mutant growth restriction is relieved by either yeast AMD1 or human AMPD2 forced expression.
(C) 10-fold serial dilutions of amd1mutant yeast transformed with tetracycline-regulated expression ofAMD1WTor corresponding humanmutations on adenine-
supplemented media in presence of 0.1 mg/ml of doxycycline. Forced expression of WT, but not patient mutations, rescues growth restriction.
(D) Immunoblot analysis of AMPD2 levels in affected (A) and unaffected (U) fibroblasts. Tubulin is shown as loading control. Affected show absent or near-absent
AMPD2. Corresponding AMPD2 mutations are listed below each family.
(E) Reduced AMP deaminase activity in affected (A) compared with related unaffected (U) fibroblasts, measured by standard colorimetric AMP deaminase assay.
Top: blue intensity represents relative activity. Bottom: quantification of activity ±SD for three independent experiments. *p < 0.05 and **p < 0.005; Student’s t test.
See also Figure S2.in the presence of exogenous AMP (Kirkwood et al., 2012), we
found reduction of 80%–90% of activity (Figure 2E), suggesting
no compensatory effect by AMPD3 expression in these cells
(Figure S2D). We conclude that patient cells show severe reduc-
tions in AMPD2 levels and AMP deaminase activity.
Survival Is Compromised in Challenged AMPD2
Mutant Cells
The near-complete absence of enzymatic AMPdeaminase activ-
ity prompted a search for a phenotype in patient cells. However,
we found that cell growth and survival of fibroblasts were unaf-
fected under basal growth conditions and found no evidence
of altered purine nucleotide levels (Figures S3A and S3B). The
amd1 yeast mutant shows growth restriction only in the pres-
ence of exogenous adenine, which feeds directly into AMP
through APRT (Alfonzo et al., 1997). Thus, we considered that508 Cell 154, 505–517, August 1, 2013 ª2013 Elsevier Inc.addition of exogenous purines to these cells might uncover rele-
vant phenotypes. We utilized adenosine, which is both bioavail-
able and feeds into AMP through adenosine kinase (Figure 3A),
and found a dose-dependent effect on cell survival in patient
fibroblasts in the range of 50–500 mM concentrations, dropping
to about half of untreated survival rates. Cells from unaffected
family members showed no effect of adenosine at these concen-
trations (Figures 3B and 3C). We conclude that, like the yeast
amd1 mutant, metabolic stress is required to uncover pheno-
typic consequences in AMPD2 mutant cells.
To study the mechanism of human neuronal vulnerability in
AMPD2 mutants, we generated induced pluripotent stem cells
(iPSCs) from families PCH-1298 and PCH-1236 and from both
affected (AMPD2 homozygous mutants) and unaffected (hetero-
zygous controls). Because there is generalized brain affection in
PCH9 patients (including microcephaly and corpus callosum
Figure 3. Adenosine Supplementation Reduces Viability of AMPD2-Deficient Patient-Derived Cells
(A) Schematic of nucleotide metabolic pathway. The red arrow indicates enzymatic reaction catalyzed by AMPD2, mutated in PCH patients. Ado, adenosine;
Gua, guanine; Guo, guanosine: Ino, inosine; Hyp, hypoxanthine; and PRPP, Phosphoribosyl pyrophosphate.
(B) Survival of unaffected and affected fibroblasts from families PCH-1298 and PCH-1236, cultured with escalating adenosine concentrations for 72 hr. Mean ±
SD (four independent replicates).
(C) Bright-field images for affected PCH-1298 and PCH-1236 fibroblasts in standard medium or 50 mM adenosine-supplemented medium, documenting a
modest drop in survival.
(D) Bright-field images for PCH-1298 and PCH-1236 unaffected and affected derived iPSC and neural rosettes (NR). PAX6 (green) and NESTIN (red) immuno-
staining in neural progenitor cells (NPCs), corresponding to one unaffected and one affected clone per family.
(E) Survival rates of unaffected and affected NPCs from families PCH-1298 and PCH-1236, cultured with escalating adenosine concentrations for 72 hr, which
show a 10-fold increase in sensitivity to adenosine concentrations of NPCs compared with fibroblasts. Mean ± SD (three clones assayed at least in
quadruplicates).
(F) Bright-field images for affected PCH-1298 and PCH-1236 NPCs in standard medium or in 10 mM adenosine-supplemented medium, documenting severely
reduced survival.
See also Figure S3 and Tables S1 and S3.involvement), we reasoned that standard neural-induction-pro-
tocol-derived cells might capture the neuronal vulnerability
observed in patients. We demonstrated expression of pluripo-
tencymarkers, differentiation to three germ layers after embryoid
body formation, and generation of neural progenitor cells (NPCs)
using standard methods of derivation (Chambers et al., 2009)
(Figures 3D and S3C). Growth rates and purine nucleotide levels
were indistinguishable in standard culture medium (Figures S3D
and S3E), as were survival of neural progenitor cells. We
confirmed the absence of AMPD2 and a nearly complete loss
of AMP deaminase activity (Figure S3F).
Standard NPC medium lacks adenosine (Table S3), whereas
concentrations from 20 nM to 300 mM are well documented inmammalian brain (Rathbone et al., 1999). Thus, we tested a
range of adenosine concentrations and found that the survival
of AMPD2 mutant, but not control NPCs, dropped considerably
at concentration as low as 5 mM (Figures 3E and 3F), which is an
order of magnitude more sensitive than the isogenic patient
fibroblasts. To test for specificity of the effect, we transduced
affected NPCs with either AMPD2 or a fluorescent tag and found
restoration of survival specifically following AMPD2 transduction
(Figure S3G). Thus, the addition of physiological adenosine
concentrations to the AMPD2 mutant cells can recapitulate
the neural-specific defect observed in patients, providing a
model to further explore the underlying mechanisms leading to
neurodegeneration.Cell 154, 505–517, August 1, 2013 ª2013 Elsevier Inc. 509
Figure 4. Adenosine Supplementation Induces Adenosine Nucleotide Accumulation and Severe Guanine Nucleotide Depletion in AMPD2
Mutant Patient Cells
(A–D) Percentage of adenosine (A andC) or guanine (B andD) nucleotide levels measured by HPLC in affected and unaffected fibroblasts or NPCs cultured with or
without adenosine for 5 hr. Gray, unaffected; red, affected. Mean ± SD of two or four (A and B) and three (C and D) replicates; *p < 0.05, **p < 0.005, and ***p <
0.0005; Student’s t test.
(E) Graphical representation of liquid chromatography-tandemmass spectrometry (LC-MS/MS) data. Concentrations were used to calculate the fold change (FC)
of each metabolite in 10 mM versus 0 mM adenosine treatment, represented in log scale. Average log2(FC) for two affected clones in family PCH-1298 (top) and
family PCH-1236 (bottom) (y axis) and two unaffected clones (x axis) from family PCH-1298. Dashed lines, arbitrarily defined correlation threshold. Gray dots
within the dashed lines are metabolites with roughly the same changes in affected (A) versus unaffected (U). Red dots indicate metabolites that significantly
decrease in affected NPCs. Guanine nucleotides and IMP are consistently reduced (red) in affected NPCs.
See also Figure S4 and Tables S4 and S5.Altered Adenosine and Guanine Nucleotides in AMPD2
Mutant Cells
We predicted that cellular uptake of adenosine is necessary for
cellular toxicity in AMPD2 mutant cells. We thus treated NPCs
with 5-Iodotubercidin to inhibit adenosine uptake and found
that it efficiently blocked adenosine toxicity (Figure S4A). In
contrast, treatment with the adenosine receptor antagonist
CSG15943 did not rescue adenosine-mediated toxicity, and
the class P1 purinergic receptor agonist 5‘-(N-ethylcarboxa-
mido)-adenosine (NECA) was not sufficient to compromise
survival (Figures S4A and S4B). We conclude that intracellular
accumulation of adenosine and derived nucleotides—and not
activation of purinergic signaling through cognate receptors—
underlies the neurotoxicity.510 Cell 154, 505–517, August 1, 2013 ª2013 Elsevier Inc.Because AMPD2 executes AMP deamination, inactivating
mutations predict an accumulation of adenosine nucleotides.
We measured nucleotide levels in patient fibroblasts treated
with 50 mMadenosine (the lowest toxic dose) and found elevated
ATP levels, which were more striking in AMPD2 homozygous
mutant cells compared with heterozygous control cells (Fig-
ure 4A). As expected by the inability to deaminate AMP to IMP,
there was also a corresponding decrease in guanine nucleo-
tides, which was again more striking in homozygousmutant cells
(Figure 4B). The results were similar in NPCs cultured with 10 mM
adenosine for 5 hr (a time before compromised viability; Fig-
ure S4C). Patient NPCs showed a slight increase in adenosine
nucleotides—most notably for ATP (Figure 4C)—and showed a
dramatic reduction in guanine nucleotides—most remarkable
for GTP—which was reduced by half (Figure 4D). These demon-
strate that patient cells show adenosine-dependent accumula-
tion of specific adenosine nucleotides and depletion of guanine
nucleotides.
De Novo Purine Biosynthesis Is Inhibited in AMPD2
Mutant NPCs
The previous results led us to question why guanine nucleotide
levels were reduced only in the presence of exogenous adeno-
sine. In order to assess metabolic profiles more completely, we
developed a quantitative mass spectroscopy panel of 140
metabolites (Table S4) and tested in unaffected and affected
NPCs untreated and treated with two different adenosine con-
centrations. Adenosine itself, despite addition to the culture
media, remained below detectable level, suggesting efficient
cellular processing.Manyof the analyzedmetabolites responded
to adenosine treatment similarly in unaffected and affected cells,
probably reflecting shared metabolism. However, in accordance
with HPLC data, adenosine nucleotide pools were increased
slightly, and guanine nucleotide pools were notably decreased
in homozygousmutant NPCs (Figures 4E andS4D and Table S5).
Purine nucleotides can exert inhibitory feedback on the de
novo pathway by inhibiting phosphoribosyl pyrophosphate
(PRPP) synthetase and PRPP amidotransferase (Watts, 1983).
We thus considered whether the accumulated adenosine nucle-
otides might additionally inhibit de novo purine biosynthesis,
which could explain why adenosine treatment reduces guanine
nucleotide levels. Several lines of evidence support this model.
First, IMP was one of the most reduced compounds in affected
NPCs compared with unaffected NPCs, suggesting a failure of
the de novo synthesis pathway to generate IMP. Second, IMP
should theoretically be salvaged from hypoxanthine and PRPP
by the HGPRT enzyme (Figure 3A). Despite the presence of
hypoxanthine in the culture media, IMP was not replenished
and cell growth was restricted, suggesting that PRPP, which is
synthesized by PRPP synthetase in the first step of the de
novo pathway, is in limiting amounts. Third, 5-Aminoimidazole-
4-carboxamide riboside (AICAr, i.e., dephosphorylated AICAR),
an intermediate of de novo synthesis, was more severely
reduced in affected NPCs than in unaffected NPCs treated
with adenosine (Figure S4E). Finally, genome-wide expression
profiles were compared with and without treatment. Despite a
few notable alterations, suggesting mostly acute biochemical
and/or posttranscriptional derangements, there was an increase
in IMPDH2 levels (Figures S5A–S5C), which is known to increase
upon guanine nucleotide depletion to support conversion of IMP
to GMP (Escobar-Henriques and Daignan-Fornier, 2001).
Whereas the activity of de novopurine biosynthesis enzymes is
high in proliferating cells such as NPCs, it is much lower in post-
mitotic cells in general and in adult mammalian brain in particular
(Watts, 1983). We predicted that, if feedback inhibition contrib-
utes to the phenotype in proliferating NPCs, postmitotic neurons
might be impervious to adenosine treatment. Both control- and
patient-derived NPCs were induced toward neuronal differentia-
tionandacquired indistinguishable axon- anddendrite-like struc-
tures (Figure S4F). Exposure to adenosine in themedium had just
a slight effect on survival that was not distinguishable from the
effect in control cells at either 15 or 30 day time points (Fig-ure S4G). Together, the data suggest that blockage of de novo
purine nucleotides contributes to the cellular toxicity and guanine
nucleotide depletion observed in patient cells.
AMP Deaminase Deficiency Associates with Altered
Nucleotide Levels and Degeneration in Brain
In order to determine whether these alterations in nucleotide
levels are apparent in intact brain, we studied Ampd2 and
Ampd3 knockout (KO) mice (Cheng et al., 2012; Toyama et al.,
2012). The absence of histological phenotype inAmpd2KObrain
(Figure 5A) and the coexpressionofAmpd2 andAmpd3 in embry-
onic and postnatal mouse brains, both contributing equally to
brain AMP deaminase activity (Figures 5B and 5C), prompted
us to test for functional redundancy by generating Ampd2 and
Ampd3 double-knockout mice (DKO), which were born in the ex-
pected Mendelian ratio. Early after birth, DKOs were distinguish-
able from wild-type (WT) littermates by slightly reduced body
weight and severely shortened lifespan limited to 2 or 3 weeks
(Figure 5D). Besides the slightly reduced brain size, which is
consistent with the body size reduction, Ampd2/3 DKO mice
brains showed little evidence of the characteristic neuronal loss
observed in AMPD2 mutant patients. After P14, we observed a
neurodegenerative phenotype mostly affecting the CA3 pyrami-
dal neurons in the hippocampus and some sparse pyknotic cells
all over the cortex and the cerebellum (Figure 5E), which is asso-
ciated with behavioral gait disturbance (Movie S1). Investigation
of nucleotide levels in these brains at 2 weeks demonstrated a
25% increase in ATP nucleotide levels and a 33% decrease in
GTP levels in DKO compared to WT (Figure 5F). These results
indicate partial genetic redundancy for Ampd2 and Ampd3 in
the mouse brain and support a conserved role for AMP deami-
nase activity in neuroprotection through adenosine nucleotide
metabolism and/or maintenance of the guanine nucleotide pool.
AICAr Treatment Rescues Adenosine-Mediated Toxicity
in Mutant Cells
The previous data suggest accumulation of adenosine and
depletion of guanine nucleotides but did not distinguish relative
importance in neurotoxicity. We reasoned that exogenous appli-
cation of AICAr should allow us to distinguish these because this
would bypass a block in de novo synthesis toward guanine
nucleotides but only further exacerbate accumulation of adeno-
sine nucleotides through the conversion of IMP to AMP. AICAr is
bioavailable to cultured cells and is converted to AICAR through
adenosine kinase (Figure 6A). The growth phenotype of amd1
yeast was almost completely rescuedwith increasing AICAr con-
centrations (Figure 6B), suggesting impaired de novo synthesis
as a major defect.
We next examined whether patient NPCs might respond
similarly to AICAr treatments. However, because AICAr can
compete with adenosine for internalization mediated by nucleo-
side transporters (Gadalla et al., 2004), we designed a timed
protocol (Figure 6C). First, we treated patient-derived NPCs
with adenosine for 7 hr, followed by washout and culture with
standard media for an additional 17 hr. With this protocol,
survival of AMPD2 mutant NPCs was similar to cells under
continued exposure to adenosine, suggesting lingering toxicity
of adenosine. When the media were instead supplementedCell 154, 505–517, August 1, 2013 ª2013 Elsevier Inc. 511
Figure 5. AMP Deaminase Deficiency Is Associated with Postnatal Neurodegeneration and Altered Nucleotide Levels in Mouse
(A) Parasagittal cresyl-violet sections from WT, Ampd2 KO, and Ampd2/3 DKO at P20. The smaller size of the Ampd2/3 DKO whole brain (top) and cerebellum
(middle) is evident. Cerebellar lobules are labeled with roman numerals. Cell loss is visible in the CA3 region of the hippocampus in the Ampd2/3 DKO (bottom,
arrowheads). Scale bar, 0.5 mm.
(B) Quantitative PCR (qPCR) of Ampd2 and Ampd3 normalized with Actin as loading control. Fb, forebrain; Hb, hindbrain; Cb, cerebellum; and Ctx, cortex. E,
embryonic day and P, postnatal day. Mean ± SD of three replicates.
(C) AMP deaminase activity fromWT,Ampd2KO, and Ampd3KO in brain, liver, and heart.Ampd2 KO and Ampd3KO conserve about half ofWT AMPdeaminase
activity in brain. Mean ± SD of four replicates. *p < 0.05 and **p < 0.0005; Student’s t test.
(D) Kaplan-Meier survival curve of Ampd2/3 DKO compared to Ampd2 KO, Ampd3 KO, and WT. Mean of Ampd2/3 DKO survival is 17.8 ± 0.5 days.
(E) Parasagittal hematoxylin and eosin staining (H&E) sections fromWT and Ampd2/3DKO at P15. Scattered eosinophilic neurons are visible in the hippocampus
(top, arrowheads) and in the Purkinje cell layer of the cerebellum (bottom) of DKOs. Insets, indicate higher magnification of pyknotic cells (dark staining). GC,
cerebellar granule cell and PCL, Purkinje cell layer. Scale bar, 0.5 mm.
(F) Whole-brain nucleotide levels in P14 brains from the four genotypes. ATP levels were significantly increased (26%), and GTP levels were significantly
decreased (33%) in Ampd2/3 DKO. Mean ± SD of three replicates.
See also Movie S1.with AICAr, we noted concentration-dependent rescued viability
(Figure 6D). Concurrently, following the AICAr protocol, guanine
nucleotide levels were restored to near-normal levels (Figure 6E),
and the genome-wide expression profile demonstrated partial
restoration of the IMPDH2 level (Figure S5C and Table S6), sug-
gesting relief of cellular stress.
AMP protein kinase (AMPK) activation is a well-documented
effect of AICAr, which was also observed in affected NPCs (Fig-512 Cell 154, 505–517, August 1, 2013 ª2013 Elsevier Inc.ure S5D). However, substituting AICAr with Metformin, an AMPK
activator that does not directly feed into de novo purine synthe-
sis, failed to rescue adenosine-mediated toxicity (Figure S5E),
excluding AMPK activation as a rescue mechanism. This,
together with confirmation by mass spectroscopy that IMP is
significantly restored by AICAr treatment (Figure 6F), supports
de novo purine synthesis as the major target for guanine nucle-
otide replenishment in AMPD2 mutant cells.
Figure 6. AICAr Treatment Restores Cell Growth in Yeast and Viability in Patient NPCs
(A) Schematic of purine nucleotide metabolic pathway highlighting the inhibitory effect of adenosine nucleotides on de novo synthesis pathway (red) and the
metabolic route for AICAr (green) in AMPD2-deficient cells.
(B) Culture of identical concentration of WT and amd1 yeast cells in the presence of adenine, demonstrating rescue of growth defects upon increasing AICAr
concentration.
(C) Schematic of AICAr rescue experimental protocol in human NPCs. Adenosine was added at time 0 hr and then washed out at 7 hr and replaced with AICAr.
Metabolites and survival were analyzed at 14 and 24 hr, respectively.
(D) Improved survival of affected NPCs treated with increasing AICAr concentrations. Graph represents mean ± SD from two clones assayed at least in
quadruplicates. Bottom indicates bright-field images of cells demonstrating increase in cell survival upon AICAr treatment.
(E) Percentage of adenosine or guanine nucleotide levels measured by HPLC in affected NPCs, cultured in adenosine for 7 hr followed by standard medium
(NBF) or AICAr 500 mM. Data are compared to 7 hr adenosine + 7h standardmedium tominimize the contamination from non-viable NPCs in longer cultures. GMP
was nondetectable under all conditions and is thus not shown. Mean ± SD for three clones derived from PCH-1298 and PCH-1236 family affected NPCs. **p <
0.005; Student’s t test.
(F) Graphical representation of LC-MS/MS data. Concentrations were used to calculate the FC of each metabolite in 10 mM adenosine+standard medium (NBF)
(x axis) or 10 mMadenosine+500 mMAICAr (y axis) versus NBF. Average log2(FC) for two affected (A) clones from each family PCH-1298 (left) and family PCH-1236
(right). Dashed lines indicate arbitrarily defined correlation threshold. Green and red dots indicate metabolites outside the threshold limits that significantly
increase (green) or decrease (red) with AICAr. Guanine nucleotides and IMP are significantly higher in affected NPCs that receive AICAr for 7 hr after adenosine
challenge. Metabolites outside the graph scale are not represented (i.e., AICAr).
See also Figure S5 and Table S6.Translation Initiation Is Blocked in AMP
Deaminase-Deficient Cells
Because the established PCH genes implicate defective protein
synthesis and because GTP is the main energy source in protein
synthesis, we considered that GTP depletion could impair pro-tein synthesis in AMPD2mutant PCH patients. Protein synthesis
can be assessed at a global level using [35]S-methionine meta-
bolic labeling, which showed a severe defect in patient-derived
NPCs following adenosine treatment (Figure 7A). This finding
was confirmed in the amd1 yeast strain, which showed aCell 154, 505–517, August 1, 2013 ª2013 Elsevier Inc. 513
Figure 7. AMPD2 Deficiency Results in Translation Initiation Blocking
(A) Metabolic labeling with [35S]-Methionine of NPCs shows reduced incorporation in affected (A) compared with unaffected (U) in presence of adenosine
(+ indicates 10 mM for 5 hr). Top, [35S] autoradiogram. Bottom, Coomassie staining. The graph indicates autoradiogram quantification normalized for total protein
for three NPC clones.
(B) Metabolic labeling with [35S]-Methionine of yeast cells grown in SD-CASA media supplemented with adenine. Mycophenolyc acid (MPA 30 mg/ml; inhibits
guanine nucleotide synthesis) was used as positive control. A decrease of 41% in the rate of incorporation of [35S]-Methionine in amd1 strain is rescued by AICAr
incubation prior to metabolic labeling in a time-dependent fashion, whereas no difference was detected in the absence of adenine (right).
(C) Representative polysome profiles of WT and amd1 mutant strains grown with adenine. Polysome (P) and monosome (M; 80S peak) profiles were quantified
from three independent experiments. Polysome to monosome ratio (P/M) suggests a defect in protein translation initiation (right).
(D) Metabolic labeling with [35S]-Methionine of WT and sen2-41 mutant at nonpermissive temperature.
*p < 0.05 and **p < 0.0005; Student’s t test; all graphs show mean ± SD.decrease of 40% incorporation in acid-insoluble material—a
defect completely rescued in a time-dependent fashion with
the addition of AICAr in the culture media (Figure 7B).
In order to understand this mechanism, we analyzed polyribo-
some profiles from amd1 andWT strains and found a decrease in
the relative amount of actively translating ribosomes (considered
as the polyribosome) in the amd1 mutant (Figure 7C). The
decreasing ratio of polyribosome over monosome (80S peak)
in the mutant cells (2.9 and 1.7 for WT and amd1 strains, respec-
tively) suggested a defect in protein translation initiation, as
has been documented for eIF2 (eukaryotic translation initiation
factor 2) GTP-dependent activation (Foiani et al., 1991) or gua-
nine-nucleotide-depleted cells caused by GMP synthase muta-
tion (Iglesias-Gato et al., 2011). As a comparison, we evaluated
a SEN2 mutant encoding a highly conserved member of the
tRNA splicing endonuclease (SEN) complex in yeast, which is514 Cell 154, 505–517, August 1, 2013 ª2013 Elsevier Inc.orthologous to the human TSEN2 gene and mutated in PCH
type 2 (MIM: 608753). We found that the temperature-sensitive
mutant sen2-41, which affects tRNA splicing (Yoshihisa et al.,
2003), also showed a pronounced decrease in [35]S-methionine
metabolic labeling at a nonpermissive temperature (Figure 7D),
suggesting the protein translation defect as a common mecha-
nism in PCH.
DISCUSSION
Neuronal Vulnerability in AMPD2 Mutants
Adenosine toxicity is a well-recognized consequence of meta-
bolic derangements and includes a number of downstream
consequences such as pyrimidine/purine starvation and defects
in methylation (Archer et al., 1985). Our study demonstrates that
neural cells deficient in AMPD activity are exquisitely sensitive to
adenosine, which is generated in neural tissue by physiological
processes such as active methylation and synaptic activity
(Rathbone et al., 1999). The vulnerability of AMPD2mutant neu-
rons to physiological levels of adenosine, mediating cellular
growth restriction followed by cell death, is likely a consequence
of guanine nucleotide depletion.
Why do humans show specific vulnerabilities of brainstem
structures to AMPD2 mutations? This may reflect regional dif-
ferences in expression of other AMPD paralogs. Indeed,
although AMPD2 and AMPD3 are coexpressed in the devel-
oping human cerebral cortex, AMPD2 is predominant in the
cerebellum (Figure S2A). This, however, does not apply for the
mouse brain, in which the two paralogs—present in cortex
and cerebellum—contribute equally to brain AMP deaminase
activity. Accordingly, we only observe neuronal vulnerability,
resulting in ataxia and cell loss, when both Ampd2 and
Ampd3 are deleted in mice. This is reminiscent of HPRT defi-
ciency, which leads to Lesch-Nyhan syndrome in humans but
to which mice show no consequence unless additional purine
metabolism enzymes are pharmacologically inhibited (Wu
and Melton, 1993). Thus, although the simplest interpretation
is that vulnerability to AMPD2 mutations is uncovered when
AMPD3 compensatory effect is lacking, there may be additional
buffering of purine metabolism vulnerability in mice.
Protein Translation Impairment and Neurodegeneration
Known mutations in a wide range of animal models and human
disorders suggest misregulation of protein translation as a path-
ogenic mechanism of neurodegeneration. In the sticky mouse,
neurodegeneration is caused by the mutation of an amino-
acyl-tRNA synthetase, which disrupts translation fidelity and
causes accumulation of misfolded proteins (Lee et al., 2006).
Mutations in the protein synthesis factor Eef1a2 cause neuro-
degeneration in the Wasted mouse, presumably due to a tis-
sue-specific block of protein translation (Scheper et al., 2007).
Similarly, in humans, the five EIF2B genes that encode transla-
tion initiation factors are each mutated in childhood ataxia
with central nervous system hypomyelinization (CACH, MIM:
603896). In PCH, the most common mutations fall in three of
the four known subunits of tRNA endonuclease complex
(TSEN54, TSEN34, and TSEN2) (Budde et al., 2008), which pre-
sumably affect tRNA processing and downstream protein trans-
lation but are not yet demonstrated in patient cells. Although we
did not fully explore other global consequences of GTP
depletion such as on RNA or DNA synthesis (Cohen et al.,
1981), our identification of similar protein synthesis defects in
AMP deaminase-deficient cells and in yeast mutant for sen2
(TSEN2 ortholog) suggests that reduced protein synthesis
may be a common pathogenic mechanism for neurodegenera-
tion in PCH.
Enhancement of De Novo Purine Biosynthesis
as Therapeutic Target
We identified deficiency in guanine nucleotides as central to the
AMPD2 pathogenesis and linked this to defective protein syn-
thesis. There are other requirements for guanine nucleotides
to meet cellular energy and signaling demands, including G pro-
tein signaling and microtubule polymerization, which we do notevaluate here. Deficiency of guanine nucleotides as central to
the pathogenesis was supported by AICAr treatment, which
rescues GTP depletion, protein synthesis block, and cell sur-
vival phenotypes. Might this serve as a potential treatment in
patients? AICAr is proven to be beneficial for exercise endur-
ance by means of AMPK activation, the master regulator of
cellular energy metabolism (Narkar et al., 2008). However, by
targeting the same pathway, AICAr can inhibit axon growth in
mouse cultured cortical neurons (Williams et al., 2011). AICAr’s
effects on nucleotide metabolism are disparate, showing
biphasic effects on cell survival by inhibition of pyrimidine nucle-
otide biosynthesis (Thomas et al., 1981). Therefore, if AICAr is to
be used therapeutically, thorough evaluation of effective
nontoxic dosage would be required. Although AICAr’s potential
as therapeutic treatment remains to be studied, enhancing de
novo purine biosynthesis might be efficient in the treatment of
PCH type 9.
EXPERIMENTAL PROCEDURES
Patient Recruitment
Patients were enrolled and sampled according to standard local practice in
approved human subject protocols at the University of California.
Exome Sequencing
DNA was extracted from peripheral blood leukocytes by salt extraction. Exon
capture, sequencing, variant calling, and filtering were performed as previ-
ously described (Dixon-Salazar et al., 2012). For specific details, see Extended
Experimental Procedures.
Yeast Strains and Culture Conditions
To generate the S. cerevisiae amd1 mutant strain, the AMD1/YML035C ORF
was replaced by PCR-based gene targeting with the hphNT1 marker (Janke
et al., 2004) in the haploid reference strain BY4741. Yeast cultures were grown
as described (Saint-Marc et al., 2009). For specific details, see Extended
Experimental Procedures.
Fibroblast Culture, iPSC, and NPC Generation
Fibroblasts were generated from unaffected and affected dermal biopsies
explants. iPSCs, neural progenitor cells, and neurons were obtained as previ-
ously described (Chambers et al., 2009; Okita et al., 2011). For specific details,
see Extended Experimental Procedures.
Mouse
Animal use followedNIH guidelines andwas approved by IACUCat the Univer-
sity of California, San Diego. Ampd2(/) mice were previously generated
(Toyama et al., 2012), and Ampd3(/) were either generated by us using
embryonic stem (ES) cell clone EPD0043_3_B02 generated by the Wellcome
Trust Sanger Institute (https://www.komp.org/) or from previous publication
(Cheng et al., 2012).
Growth Curve and Cell Survival
Modified MTTmethod (Carmichael et al., 1987) was used for growth curve and
survival analysis, which is detailed in the Extended Experimental Procedures.
AMP Deaminase Activity Assay
AMP deaminase activity was performed as previously described (Kirkwood
et al., 2012) with minor modifications detailed in the Extended Experimental
Procedures.
Nucleotide Analysis by HPLC
Nucleotide extraction was performed as previously described (Fairbanks et al.,
2002), and nucleotides were analyzed by high-performance liquid chromatog-
raphy (HPLC). For specific details, see Extended Experimental Procedures.Cell 154, 505–517, August 1, 2013 ª2013 Elsevier Inc. 515
Liquid Chromatography-Tandem Mass Spectrometry
Metabolites were extracted with 80:20/0.1% Methanol:Water/Formic acid
precooled to 80C and 13C-Labeled E. coli extract as an internal standard.
Chromatographic separation was achieved using a UFLC XR HPLC
(Shimadzu), and compounds were detected and quantified on an AB SCIEX
Qtrap 5500 mass spectrometer (AB SCIEX). For specific details, see Extended
Experimental Procedures.
Polysome Profiling
Yeast extracts were prepared as described (Esposito et al., 2010). Typically,
10 OD260 of nucleic acid were loaded onto an 11 ml linear sucrose gradient
(10 to 50% w/v) and centrifuged using SW40Ti rotor (Beckman) at
39,000 rpm for 160 min at 4C. Sample tubes were loaded on a tube piercer
after priming the system with 55% sucrose, and a flow rate of 800 ml/min
was set on the peristaltic pump. Absorbance at 254 was monitored using an
Econo UV monitor (BioRad), and data were collected and analyzed with the
WinDaq software (DATAQ Instruments).
ACCESSION NUMBERS
Exome data are available at NCBI’s dbGaP (http://www.ncbi.nlm.nih.gov/gap)
under the study phs000288. Raw gene expression array data have been
deposited to NCBI’s Gene Expression Omnibus (http://www.ncbi.nlm.nih.
gov/geo/) under the study GSE46615.
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